Chapman W C, Clavien P A, Fung J, Khanna A, Bonham A
Vanderbilt University School of Medicine, Oxford House, Suite 801, Nashville, TN 37232-4753.
Arch Surg. 2000 Oct;135(10):1200-4; discussion 1205. doi: 10.1001/archsurg.135.10.1200.
A novel collagen-based composite of bovine microfibrillar collagen and bovine thrombin combined with autologous plasma is more effective than standard hemostasis (collagen sponge applied with pressure) in controlling diffuse hepatic bleeding after hemihepatectomy or segmental resection of the liver.
Randomized controlled trial.
Seven university-affiliated medical centers.
Sixty-seven adult patients scheduled for hemihepatectomy or segmental resection who received hemostatic intervention with an investigational treatment (n = 38) or control (n = 29).
Bleeding hepatic tissue was managed in all control subjects with a collagen sponge with manual pressure. Subjects in the experimental group had the sprayable liquid composite intraoperatively applied to the surgical site. The liquid immediately formed a collagen-fibrin gel that was used without concomitant tamponade.
Hemostatic success was defined as the proportion of subjects in each treatment group who achieved complete hemostasis within 10 minutes. Success rates and median times required to achieve controlled bleeding (ie, slight oozing) and complete hemostasis were compared between treatment groups.
All 38 subjects in the experimental group achieved complete hemostasis within 10 minutes compared with only 69% (20/29) of control subjects (P<.001). The median time to controlled bleeding was approximately 4 times longer (250 vs 62 seconds) for control subjects than for experimental group subjects (P<.001). The median time required to achieve complete hemostasis also favored the experimental group (150 vs 360 seconds; P<.001). No adverse events related to the use of the experimental hemostatic agent were detected.
The experimental composite is more effective at controlling and stopping diffuse hepatic bleeding than a collagen sponge applied with pressure; it may be a useful hemostatic agent for patients undergoing hemihepatectomy, segmental resection, and related surgical procedures.
一种新型的基于牛微原纤维胶原蛋白和牛凝血酶并结合自体血浆的胶原蛋白基复合材料,在控制半肝切除或肝段切除术后的弥漫性肝出血方面,比标准止血方法(施加压力的胶原蛋白海绵)更有效。
随机对照试验。
七家大学附属医院。
67例计划进行半肝切除或肝段切除的成年患者,他们接受了试验性治疗(n = 38)或对照治疗(n = 29)的止血干预。
所有对照组受试者使用施加手动压力的胶原蛋白海绵处理出血的肝组织。实验组受试者术中将可喷雾的液体复合材料应用于手术部位。该液体立即形成胶原蛋白 - 纤维蛋白凝胶,使用时无需同时进行填塞。
止血成功定义为每个治疗组中在10分钟内实现完全止血的受试者比例。比较治疗组之间实现控制出血(即轻微渗血)和完全止血所需的成功率和中位时间。
实验组的所有38名受试者在10分钟内实现了完全止血,而对照组仅69%(20/29)的受试者达到这一效果(P <.001)。对照组实现控制出血的中位时间比实验组受试者长约4倍(250秒对62秒;P <.001)。实现完全止血所需的中位时间也有利于实验组(150秒对360秒;P <.001)。未检测到与使用试验性止血剂相关的不良事件。
该试验性复合材料在控制和停止弥漫性肝出血方面比施加压力的胶原蛋白海绵更有效;它可能是对半肝切除、肝段切除及相关手术患者有用的止血剂。